Inhibrx Biosciences Inc. Common Stock (INBX)

FairStock Score: 41/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the 2026-10-26 close of $88.61, Inhibrx carries a $1.3B market value against a business that is still experimental. In fiscal 2025, the year ended 2025-12-31, revenue was $1.3M, net loss $140.1M, and diluted EPS -$9.04. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $36.6M and diluted EPS -$2.34, with revenue not available; in fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $33.4M and diluted EPS -$2.15. Trailing free cash flow was -$131.9M, a -10.1% FCF yield, so capital is being consumed. In fiscal 2024, the year ended 2024-12-31, Inhibrx reported net income of $1.7B and diluted EPS $112.62 on revenue of $200,000, but in fiscal 2025 it swung back to a large loss; that is why FairStock labels it TURNAROUND: a loss in the latest year after earlier profits. I do not treat the prior profit as durable without evidence. On the same 2026-10-26 close, FairStock's P/E was -9.98 and P/B 197.53. Health measures are weak: ROE -1773.60%, ROCE -43.61%, D/E 13.39, Piotroski 2/9, Altman 1.42, beta 3.67, and FairStock score 41/100. The candidates may have scientific promise, but no approved product or meaningful revenue is shown, so competitive advantage is unproven in the accounts. Valuation gives no margin of safety on current sales or book value; the $1.3B market cap is largely a bet on future clinical success. On Graham-Buffett principles, I see a speculative clinical-stage equity, not a predictable value compounder.

In plain English: Inhibrx Biosciences is an experimental drug developer working on biologic medicines for serious cancers and other life-threatening conditions. It has almost no product revenue, is losing tens of millions of dollars each quarter, and has negative cash flow, so the business looks weak on current numbers. At $88.61 a share, the price looks expensive compared with the very small revenue and large losses shown in its filings.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer